Literature DB >> 10348447

Assessment of breast tissue changes on hormonal replacement therapy using MRI: a pilot study.

J R Reichenbach1, C Przetak, G Klinger, W A Kaiser.   

Abstract

PURPOSE: The purpose of this study was to investigate, using MRI, the potential morphologic effects of hormonal replacement therapy (HRT) on breast tissue in post-menopausal women.
METHOD: Five subjects were enrolled who were treated subsequently with both estrogen (2 mg/day) and a combination of estrogen (2 mg/day) and progestagen (1 mg/day). T1-weighted (TR 11 ms, TE 4.65 ms, flip angle 35 degrees, two excitations) 3D MR scans were acquired on a 1.5 T whole-body scanner before therapy and after each regimen. With use of a segmentation algorithm and histogram evaluation, parenchymal tissue/fat ratios were calculated over targeted volumes and changes were assessed.
RESULTS: An increase in these ratios was observed in two subjects after receiving the combined therapy, indicating a change in parenchymal pattern, whereas no obvious changes were detected in any of the subjects during the estrogen-based therapy.
CONCLUSION: MRI is able to detect and quantitate changes in breast parenchyma during HRT.

Entities:  

Mesh:

Year:  1999        PMID: 10348447     DOI: 10.1097/00004728-199905000-00015

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  9 in total

1.  Contrast enhancement kinetics of normal breast parenchyma in dynamic MR mammography: effects of menopausal status, oral contraceptives, and postmenopausal hormone therapy.

Authors:  Katrin Hegenscheid; Carsten O Schmidt; Rebecca Seipel; René Laqua; Ralf Ohlinger; Norbert Hosten; Ralf Puls
Journal:  Eur Radiol       Date:  2012-07-08       Impact factor: 5.315

2.  Are Qualitative Assessments of Background Parenchymal Enhancement, Amount of Fibroglandular Tissue on MR Images, and Mammographic Density Associated with Breast Cancer Risk?

Authors:  Brian N Dontchos; Habib Rahbar; Savannah C Partridge; Larissa A Korde; Diana L Lam; John R Scheel; Sue Peacock; Constance D Lehman
Journal:  Radiology       Date:  2015-05-12       Impact factor: 11.105

3.  Normal parenchymal enhancement patterns in women undergoing MR screening of the breast.

Authors:  Sanaz A Jansen; Vicky C Lin; Maryellen L Giger; Hui Li; Gregory S Karczmar; Gillian M Newstead
Journal:  Eur Radiol       Date:  2011-02-17       Impact factor: 5.315

4.  Influence of Menstrual Cycle Timing on Screening Breast MRI Background Parenchymal Enhancement and Diagnostic Performance in Premenopausal Women.

Authors:  Brian N Dontchos; Habib Rahbar; Savannah C Partridge; Constance D Lehman; Wendy B DeMartini
Journal:  J Breast Imaging       Date:  2019-06-11

5.  Development and validation of an algorithm for registration of serial 3D MR breast data sets.

Authors:  Jürgen R Reichenbach; Jens Hopfe; Matthias E Bellemann; Werner A Kaiser
Journal:  MAGMA       Date:  2002-06       Impact factor: 2.533

6.  Effects of Neoadjuvant Chemotherapy on Benign Breast Lesions Compared to Cancers: Should an Additional Lesion on Magnetic Resonance Imaging Responding Similar to Cancer after Neoadjuvant Chemotherapy be Viewed with Suspicion?

Authors:  Rebecca Leddy; Abid Irshad; Lara Hewett; Heather Collins; Frank Vento; Susan Ackerman; Madelene Lewis
Journal:  J Clin Imaging Sci       Date:  2016-09-20

7.  Changes in magnetic resonance mammography due to hormone replacement therapy.

Authors:  Stefan O R Pfleiderer; Steffen Sachse; Dieter Sauner; Christiane Marx; Ansgar Malich; Susanne Wurdinger; Werner A Kaiser
Journal:  Breast Cancer Res       Date:  2004-03-16       Impact factor: 6.466

8.  MRI Background Parenchymal Enhancement Is Not Associated with Breast Cancer.

Authors:  Barbara Bennani-Baiti; Matthias Dietzel; Pascal Andreas Baltzer
Journal:  PLoS One       Date:  2016-07-05       Impact factor: 3.240

Review 9.  Current applications and future direction of MR mammography.

Authors:  P J Kneeshaw; L W Turnbull; P J Drew
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.